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Abstract: Gout is currently the most frequent cause of inflammatory arthritis worldwide and 
is responsible for poor health-related quality of life and loss of work productivity. It is caused 
by high levels of serum urate, leading to the deposition of monosodium urate crystals in joints 
and soft tissues. This condition is associated with acute flares and, if untreated or refractory, 
chronic and potentially destructive arthritis and tophi formation. Pegloticase is a recombinant, 
pegylated uricase used in the treatment of gout patients who fail conventional urate-lowering 
therapy. In this review, we discuss the impact of pegloticase on patient outcomes in refractory 
gout. We analyze different parameters, such as plasma uric acid concentration, frequency of 
flares, tophi reduction, pain, function, quality of life, and safety.
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Background
Although its prevalence is highly variable in different regions, gout is currently the 
most frequent cause of inflammatory arthritis worldwide. Several factors, such as 
genetic background, age, gender, dietary factors, comorbid conditions, and medica-
tions, modify the risk for the disease.1
Gout is caused by high levels of serum urate due to its overproduction (10%), 
underexcretion (90%), or both,2 leading to the deposition of monosodium urate 
crystals in joints and soft tissues, which initially cause intermittent attacks of acute 
arthritis. In the absence of effective treatment, the disease progresses into a form of 
chronic and potentially destructive arthritis and tophi formation.3 Patients with gout 
describe severe pain in the affected joints, which negatively impacts their quality 
of life (QoL), particularly physical functioning and sleep.4 As prevalence increases, 
refractory cases also become more frequent and are responsible for important loss 
of work productivity.5
Long-term management of gout aims to reduce serum urate levels (SUAs) to <6 
mg/dL – or to <5 mg/dL in patients with tophaceous gout, severe arthropathy, or 
recurrent attacks.6,7 Pharmacological treatment includes 3 classes of drugs: xanthine 
oxidase inhibitors (XOIs), which inhibit urate synthesis – allopurinol and febuxostat; 
uricosurics – lesinurad, sulfinpyrazone, probenecid (and benzbromarone in some 
countries); and the enzyme uricase – pegloticase. XOIs are the mainstay of gout 
treatment. Allopurinol has long been the first-line urate-lowering therapy (ULT), 
considering its efficacy, safety profile, wide availability, and low cost.8 However, 
the small risk of severe cutaneous adverse reactions, drug interactions such as with 
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azathioprine, and the major renal excretion, requiring dose 
adjustment, limit allopurinol use in some patients. Severe 
cutaneous hypersensitivity reactions are a rare side effect 
and are more common among patients of specific Asian 
backgrounds who are positive for the human leukocyte 
antigen B*5801 allele.9,10 Febuxostat has comparable effi-
cacy to allopurinol in reducing serum urate, with lower risk 
of hypersensitivity reactions.11,12 In fact, a network meta-
analysis comparing different ULTs found febuxostat to be 
the most efficacious and safe.13 However, due to its higher 
cost, it is often reserved for patients in whom allopurinol 
was inefficient, contraindicated, or caused adverse reac-
tions.14 Uricosurics decrease serum urate by inhibiting renal 
reabsorption and therefore increasing renal excretion; they 
are a useful option for patients who cannot tolerate XOIs 
or in association with them.15,16
Uricase is an enzyme present in most non-primate 
mammals that converts urate into the more soluble product 
allantoin, which is absent in humans. Rasburicase, an uri-
case derived from Aspergillus flavus, was used to prevent 
tumor lysis syndrome in patients with hematological malig-
nancies.17 However, its short half-life, potential immuno-
genicity, and limited number of studies supporting its use 
in gout patients18 limit its use in such setting. Pegloticase 
is a porcine recombinant, polyethylene glycol-conjugated 
uricase; it was approved by the US Food and Drug Admin-
istration in 2010 and by the European Medicines Agency 
in 2013 (although the marketing authorization for pegloti-
case in the European Union has been withdrawn in June 
2016 at the request of the marketing-authorization holder, 
for commercial reasons) for the treatment of patients with 
severe gout who fail conventional ULT. Both the American 
College of Rheumatology (ACR) and European League 
against Rheumatism (EULAR) recommendations advise 
the use of pegloticase in patients with severe gout and 
impaired QoL, in whom the disease cannot be properly 
treated with any other available drug, or combination, at 
the maximal dosage.6,7
Our objective is to review the available data on the impact 
of pegloticase on patient outcomes.
Methods
We performed a literature search on PubMed, using the mesh 
terms “pegloticase” [supplementary concept] OR pegloticase, 
without applying any filters. Selection criteria included both 
observational studies and clinical trials evaluating outcomes 
of treatment with pegloticase in patients with gout. We 
excluded case reports, studies in animal models, and articles 
published in languages other than English, Portuguese, Span-
ish, or French.
Results
Our search retrieved 120 articles. After reading the title and/
or abstract, 16 articles were selected for full text reading. In 
the end, 7 articles were included in this review (Table 1). 
Articles excluded were either reviews, sub-analyses of the 
studies already included, case reports, and animal studies.
We now present the results for the following outcomes: 
plasma uric acid concentration; frequency of flares; pain, 
function, and QoL; tophi resolution and safety.
Plasma uric acid concentration
In 2006, Ganson et al, from the Duke University Medical 
Center in North Carolina, published the first open-label phase 
I trial to investigate efficacy and safety of pegloticase, includ-
ing immunogenicity. In this trial, a single subcutaneous injec-
tion of 4–24 mg of the drug was administered to 13 patients 
with refractory gout (overall plasma urate concentration 
[pUAc] 11.3±2.1 mg/dL, after 2-week allopurinol washout).19 
Outcome efficacy was assessed by the magnitude of decrease 
in pUAc. By day 7 after injection, this had declined by an 
average of 8 mg/dL and had normalized in 11 subjects. At 
day 21 following injection, pUAc remained 6 mg/dL or less 
in patients receiving 8, 12, and 24 mg of pegloticase.
One year later, the same group published another phase I 
trial, evaluating pharmacokinetics and safety of intravenous 
pegloticase.20 Single infusions (at doses ranging from 0.5 
to 12 mg) were administered to 24 patients (6 cohorts of 4 
patients each). Parameters such as plasma uricase activity 
(pUox), pUAc, and the uric acid-to-creatinine ratio (Uac:Cr) 
in urine were evaluated for 21 days after administration. 
Adverse events (AEs) and the IgG antibody response to 
pegloticase were monitored for 35 days. Prior to infusion, 
the mean pUAc in all patients in this trial was 10.9±0.5 mg/
dL. Doses of 4–12 mg allowed a greater reduction of pUAc 
from a mean ± SD value of 11.1±0.6 to 1.0±0.5 mg/dL within 
24–48 hours. After day 21, the mean pUAc for all 6 dose 
cohorts remained 2.0 mg/dL, or 9.8 mg/dL below baseline.
A multicenter, open-label, randomized, parallel-group 
phase II trial evaluated the efficacy of multiple doses and 
dose regimens of pegloticase, administered by IV infusion 
in patients with refractory gout, for 12–14 weeks.21 Patients 
were randomized into 1 of 4 pegloticase treatment groups: 4 
mg every 2 weeks, 8 mg every 2 weeks, 8 mg every 4 weeks, 
and 12 mg every 4 weeks. Primary efficacy endpoint was 
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impact of pegloticase on patient outcomes in refractory gout
Table 1 Summary of main studies analyzing the outcomes of administration of pegloticase in patients with gout
Study Population Intervention Outcome Results















Plasma uricase activity: 
✓8 subjects: pUox still measurable at 21 days after 
injection
✓5 subjects: pUox not detected beyond 10 days after 
injection
Plasma urate concentration: 
✓7 days after injection: declined by an average of about 
8 mg/dL and normalized in 11 subjects
✓21 days following injection: pUAc remained 6 mg/
dL or less in patients receiving 8, 12, and 24 mg of 
pegloticase
✓inverse relationship between simultaneously measured 
pUox and pUAc
✓5 subjects with antibody against pegloticase







Six cohorts of 4 
patients receiving 
single intravenous 
infusions of 0.5, 1, 









✓Doses of 4–12 mg: pUAc fell from 11.1±0.6 to 1.0±0.5 
mg/dL
✓Maximum pUox linearly related to the iv dose of 
pegloticase
✓Uac:Cr ratio in urine fell in parallel with the pUAc
✓9 patients with igG antibodies to pegloticase
✓20 gout flares in 14 study patients









with pegloticase 4 mg 
every 2 weeks, 8 mg 
every 2 weeks, 8 mg 
every 4 weeks, or 12 








✓Rapid reduction (within 6 hours) in pUAc to ≤6 mg/dL 
in all treatment groups
✓Sustained reduction in the 8 and 12 mg dosage groups
✓Biggest reduction in 8 mg every 2 weeks group
✓31 of 41 patients developed anti-pegloticase antibodies
✓Gout flares occurred in 88% of the patients









pegloticase 8 mg 
at each infusion 
(biweekly treatment 
group), pegloticase 8 
mg alternating with 
placebo (monthly 















of patients with 
gout flare and 
in the number 
of flares per 
patient during 
months 1–3 and 








quality of life 
(SF-36)
Proportion of pUAc responders: greater in each 
pegloticase group than the placebo group (P≤0.01)
Tophus resolution: 40% of patients in biweekly 
pegloticase group (P=0.02), 21% of patients in monthly 
pegloticase group (P=0.020), and 7% of placebo group
Incidence of gout flares and number of flares: 
✓During 1–3 months: higher for biweekly pegloticase 
group (P=0.01) and monthly pegloticase group 
(P>0.01) compared with the placebo group
✓During 4–6 months: significant reductions in the 
proportion of patients with gout flare in the biweekly 
treatment group (41%) vs the placebo group (67%) 
(P<0.007). Fewer flares per patient in biweekly 
pegloticase group (difference not significant) (P=0.32).
TJC and SJC: reductions in patients treated with 
pegloticase compared with placebo, but only differences 
in TJC were statistically significant (P=0.01)
Quality of life: 
✓Biweekly treatment: statistically significant mean 
improvements in PtGA pain (P=0.01), HAQ-Di 
(P<0.03), and baseline SF-36
✓Monthly pegloticase group: improvements in 
PtGA, HAQ-Di (P<0.001), and PCS scores (P<0.01)
✓Statistically significant improvements reported in 6 of 
8 SF-36 domains with biweekly pegloticase and 3 of 8 
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Study Population Intervention Outcome Results






either of 2 
replicate RCTs
Pegloticase 8 mg every 
2 weeks or every 4 











SUA levels) and 
clinical efficacy 
(gout flares and 
tophus burden)
Primary outcome: 
✓Gout flares and IRs: least common in patients with a 
sustained urate-lowering response to treatment and in 
biweekly group
Secondary outcomes: 
✓Most responders to biweekly and monthly pegloticase 
in the RCTs maintained SUA <6 mg/dL
✓Tophus burden: at the final visit, 60% of patients with 









• 7 organ 
transplant 
recipients






Five infusions of 










✓pUAc rapidly normalized in all treated patients
✓remained <6 mg/dL in 17 persistent responders
✓hyperuricemia recurred in 12 transient responders
✓improvement of symptoms after 5 infusions
✓Most common AEs: gout flares (90%) and infusion 
reactions (43%)
✓Among 27 pegloticase-naïve patients, antibodies to 
pegloticase developed in
✓1 of 7 (14%) organ transplant recipients
✓9 of 20 non-recipients








Pegloticase 8 mg 
intravenously every 




✓Reduction of tophi in all patients
✓71.40% reduction in volume of tophi
✓94.76% volume reduction in responders; 47.97% 
reduction in partial responders
Abbreviations: Aes, adverse events; HAQ-Di, Health Assessment Questionnaire-Disability index; igG, immunoglobulin G; iR, infusion-related reaction; iv, intravenous; 
OLe, open-label extension; PCS, physical component summary; PtGA, patient global assessment of disease activity; pUAc, plasma urate concentration; pUox, plasma uricase 
activity; RCTs, randomized controlled trials; SUA, serum urate level; SF-36, Medical Outcomes Study Short form-36; SJC, swollen joint count; TJC, tender joint count; 
Uac:Cr, uric acid-to-creatinine ratio.
of 6 mg/dL for at least 80% of the study period. Second-
ary efficacy endpoints were the percentage of time without 
hyperuricemia, mean plasma urate, and the relative reduction 
of the plasma urate level from baseline. A rapid reduction 
(within 6 hours) in the mean plasma urate levels to ≤6 mg/
dL was observed in all treatment groups. This reduction was 
sustained over the entire study period (to 28 days following 
the last study dose), except for the 4 mg every 2 weeks group. 
The greatest reduction was observed in the 8 mg every 2 
weeks group. Mean pUAc during treatment was 4.12±2.02 
mg/dL in the 4 mg every 2 weeks group, 1.42±2.06 mg/dL 
in the 8 mg every 2 weeks group, 3.21±2.26 mg/dL in the 
8 mg every 4 weeks group, and 3.09±2.46 mg/dL in the 12 
mg every 4 weeks group.
In 2011, the results from 2 replicate 6-month, random-
ized, double-blind, placebo-controlled, multicenter (56 
sites from US, Canada, and Mexico), phase III trials were 
published. These randomized controlled trials (RCTs) 
included 225 adult patients with chronic gout refractory 
to conventional therapy and gave the most conclusive data 
about efficacy and tolerability of pegloticase.22 Patients 
were randomized into 3 groups: pegloticase 8 mg at each 
infusion (biweekly treatment group), pegloticase 8 mg alter-
nating with placebo (monthly group), or placebo (placebo 
group). The primary efficacy endpoint was the proportion 
of responders in each pegloticase treatment group. It was 
defined as a pUAc <6.0 mg/dL for 80% of the time or longer 
during both months 3 and 6. Secondary endpoints included 
tophus resolution, reductions in the proportion of patients 
with gout flares and in the number of flares per patient dur-
ing months 1–3 and 4–6 of the trial, reductions in tender and 
swollen joint counts, and patient changes in pain, physical 
function, and QoL. The proportion of pUAc responders 
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impact of pegloticase on patient outcomes in refractory gout
biweekly treatment group; 35% [95% CI: 24–46] in the 
monthly treatment group) was greater than for the placebo 
group, which had nil responders (P≤0.01). The responders 
maintained pUAc substantially below 6.0 mg/dL for the 
entire 6-month treatment period.
A 30-month open-label extension (OLE) study enrolled 
151 patients who had completed either of the 2 RCTs (57 
[97%] patients from the biweekly pegloticase group, 55 
[93%] from the monthly treatment group, and all 39 patients 
from the placebo group). It assessed the long-term safety 
up to 3 years of treatment with pegloticase in patients with 
refractory chronic gout.23 Patients received pegloticase 8 
mg every 2 weeks (biweekly) or every 4 weeks (monthly). 
The primary outcome was safety, evaluated by the number 
of gout flares and infusion-related reactions (IRs). Second-
ary outcomes included urate-lowering (measured by pUAc 
levels) and clinical efficacy (assessed by gout flares and 
tophi burden). In the end, 149 patients received a mean of 
28 pegloticase infusions (SD=18) and were followed for a 
mean of 25 months (SD=11). Most responders to biweekly 
and monthly pegloticase in the RCTs maintained SUA <6 
mg/dL throughout the OLE study. In fact, 55% of all patients 
achieved the target range SUA at week 25 of the OLE study. 
On the contrary, in patients who lost urate-lowering efficacy, 
this happened within the first months of treatment in the 
RCTs, and urate levels for these patients remained <6 mg/
dL for the duration of the OLE study.
Another open-label phase II trial was conducted posteri-
orly, at the Duke University Medical Center, and published in 
2013.24 The objective was to evaluate dosing of intravenous 
administration of 8 mg of pegloticase, every 3 weeks, and 
to further investigate antibody response to pegloticase. This 
administration regime was consistent with pharmacokinetics 
and was effective in controlling hyperuricemia in 17 of 30 
patients (57%).
Frequency of flares
In the study by Ganson et al, 6 subjects (46%) developed gout 
flares during the 21-day period of observation after injection 
of pegloticase.19
In the second phase I trial, the most common AE was, 
again, acute gout flare (20 flares in 14 study patients, from a 
total of 24 patients).20 The mean time to onset of an initial gout 
flare was 13.6 days. No relationship was observed between 
the pegloticase dose and the time to an initial gout flare.
In the phase II trial by Sundy et al, 88% of patients 
reported one or more flares of gout during the study (86% 
in the 4 mg every 2 weeks group; 63% in the 8 mg every 
2 weeks group; 92% in the 8 mg every 4 weeks group; and 
100% in the 12 mg every 4 weeks group).21
The results from 2 phase III trials demonstrated that 
during 1–3 months, both the incidence of gout flares and 
the number of flares per patient were higher for pegloticase-
treated patients compared with the placebo group.22 Con-
versely, during 4–6 months, significant reductions were 
seen in the proportion of patients with gout flare in the 
biweekly treatment group (41%) vs the placebo group (67%) 
(P<0.007).
In the OLE study, gout flares occurred in 71% of patients, 
with the highest flare rates occurring during the first 3-month 
period.23 The number of flares diminished with continued 
treatment and these were less common in patients with a 
sustained urate-lowering response to treatment and those 
receiving biweekly pegloticase treatment.
Pain, function, and QoL
The efficacy of pegloticase on pain, physical function, and 
health-related quality of life (HRQoL) in patients with refrac-
tory chronic gout was evaluated as a secondary outcome in 
the 2 phase III trials.22 The outcome was measured at base-
line and at 13, 19, and 25 weeks. Patient global assessment 
of disease activity (PtGA) and pain were analyzed using a 
100-mm visual analogical scale, physical function by Health 
Assessment Questionnaire-Disability Index (HAQ-DI), and 
HRQoL by Medical Outcomes Study Short form-36 (SF-36). 
SF-36 includes 8 domains: physical functioning (PF), role 
physical (RP), bodily pain (BP), general health (GH), vitality 
(VT), social functioning (SF), role emotional (RE), and men-
tal health (MH), which are gathered into physical component 
summary (PCS) and mental component summary (MCS) 
scores. For each outcome, the minimum clinically important 
difference (MCID), representing the level of improvement 
that is perceptible to patients, was defined as ≥10 points on 
a 100-mm visual analogical scale. Patients who received 
pegloticase reported significant improvements in physical 
function and QoL compared with placebo. Additionally, in 
the biweekly pegloticase group, there were improvements 
in patient-reported pain, HAQ-DI scores, and SF-36 PCS 
scores.22
Strand et al performed a more detailed analysis of patient-
reported outcomes using the evidence from phase III RCTs, 
by combining values for each treatment group (biweekly 
treatment, monthly treatment, and placebo) at week 25.27 
Patients receiving pegloticase reported significant improve-
ments in physical function and HRQoL. At week 25, the 
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ments in the biweekly treatment group was 54% for PtGA 
(vs 29% in the placebo group, P=0.03), 55% for pain (vs 
27%, P=0.01), 45% for HAQ-DI (vs 16%, P<0.03), and 64% 
for SF-36 PCS scores (vs 29%, P<0.01). Patients receiving 
monthly pegloticase also presented significant improvements 
in PtGA, HAQ-DI, and PCS scores. Statistically (and clini-
cally) significant improvements were reported in 6 of 8 SF-36 
domains (PF, RP, BP, GH, VT, SF) with biweekly pegloticase 
and 3 of 8 domains (PF, RP, BP) with monthly pegloticase.27
Tophi resolution
Tophi resolution was evaluated as a secondary endpoint in the 
RCTs22 and in the OLE study,23 and the results were presented 
with more detail in a separate publication.24 The measures 
used to evaluate this endpoint were tophus complete response 
(CR) and target tophus CR (TT-CR). CR was defined as 
complete resolution of at least one tophus without develop-
ment of new tophi or progressive enlargement of any other 
tophus. TT-CR was defined as a 100% decrease in the area 
of the tophus and is reported as the number or proportion of 
all baseline tophi with CR at the specific study visit. These 
measures were obtained using Computer-Assisted Photo-
graphic Evaluation in Rheumatology (CAPER) methodology. 
Photographs of the hands and feet were taken at baseline, 
repeated at weeks 13, 19, and 25 of the RCTs, and at weeks 
13, 25, 53, 77, and 101 of the OLE study. CR was compared 
for each pegloticase dosing group vs the placebo group and 
according to the patient’s pUA response. Among 212 patients 
randomized in RCTs, 155 (73%) had one or more tophi at 
baseline. At the end of the RCTs, tophus resolution was 
reported for 40% of patients in biweekly pegloticase group 
(P=0.002 vs placebo), 21% of patients in monthly pegloticase 
group (P=0.02), and 7% of those treated with placebo. In 
OLE study, a total of 113 patients with tophi at the baseline 
were included. Tophus CR and TT-CR continued to increase 
during OLE study, reaching 70% (39/56) of patients and 55% 
(132/238) of target tophi after 1 year of treatment in patients 
receiving pegloticase during both the RCTs and OLE.24 At 
the final visit, overall tophus CR was achieved in 56 (60%) 
of 94 patients and the TT-CR in 207 (53%) of target tophus. 
In this period, responders to pegloticase in the RCTs had a 
higher TT-CR than non-responders (79% vs 27%).
Araujo et al conducted a prospective observational study 
to investigate the effect of pegloticase on resolution of tophi 
in patients with refractory gout.26 Ten patients (7 males and 
3 females) were enrolled in this study. Pegloticase 8 mg was 
administered intravenously every 2 weeks, after all other uric 
acid lowering therapy was stopped. Tophus deposits were 
evaluated by dual-energy CT scans of hands and feet before 
the first pegloticase infusion and after the last infusion. SUA 
levels were obtained before and after each infusion. Five 
patients were classified as responders (SUA level remained 
below saturation level <6 mg/dL for more than 80% of 
the treatment period) and other 5 were considered partial 
responders, losing treatment efficacy due to immunogenicity 
to pegloticase and development of infusion reactions. Tophi 
volume before therapy was 9.15±13.26 cm3 (mean±SD). 
After therapy, it reduced to 1.89+2.86 cm3 (mean±SD). 
Responders presented a 94.76% volume reduction and in 
partial responders a 47.97% reduction was found. This study 
showed that the reduction of uric acid levels by pegloticase 
effectively and rapidly resolves tophi in the musculoskeletal 
tissues of patients with advanced gout.
Safety
The most common AEs observed with pegloticase were gout 
flares and infusion reactions.
In the first phase I trial, induration and mild to moderate 
pain at the injection site occurred in 6 patients, within a few 
hours of subcutaneous injection of pegloticase, resolving 
within 24–48 hours. Five of the 13 subjects developed anti-
bodies anti-pegloticase. Interestingly, pUox declined faster in 
these patients and some of them developed hypersensitivity 
reactions.19
Twenty-two patients (92%) from the second phase I trial 
experienced AEs of mild to moderate severity. Acute gout 
flares were the most common. Other AEs in the study group 
included elevated blood pressure, dizziness, back pain, diar-
rhea, dyspepsia, and insomnia. In contrast with the previous 
trial, none of the patients experienced an infusion reaction. 
No relationship was observed between pegloticase dose and 
the risk of an AE. Nine patients developed antibodies to 
pegloticase following infusion and, again, there was evidence 
of immune mediated clearance of the drug.20
In the phase II trial, 93% of the patients reported AEs and 
their incidence was similar across all treatment regimens. 
The most common AEs were nephrolithiasis (15% of the 
subjects) and arthralgia (12%). Most AEs were considered to 
be unrelated to the study treatment (60%) and mild or moder-
ate in severity (93%). There were 13 serious AEs, reported in 
9 patients. Five of these (anemia, hypersensitivity, infected 
tophus, and gout flares [2 patients]) were considered to be 
possibly or probably related to the study drug, and 2 of them 
led to discontinuation of the treatment (infected tophus and 
hypersensitivity). Infusion-day AEs occurred in 18 patients, 
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of 13 withdrawals). The most common were muscle spasm, 
dyspnea, and hypersensitivity. No anaphylactic reactions were 
observed but one case of hypersensitivity was reported as a 
serious AE. Antibodies against pegloticase were reported 
in 31 patients (76%). These patients did not suffer allergic 
reactions; however, half-life of pegloticase was shorter and 
the rate of non-responders was higher among them.21
More than 90% of the patients experienced AEs in the 
replicate RCTs. Serious AEs were more frequent in patients 
treated with biweekly (24%; 95% CI: 15–34) and monthly 
pegloticase (23%; 95% CI: 14–33) than in patients receiving 
placebo (12%; 95% CI: 4–25). The most common AE was 
gout flare, reported in approximately 80% of patients across 
the 3 pooled study groups. Although all patients, in the phase 
III studies, received anti-histamines and corticosteroids 
before the infusion, IR was the second most common AE. 
This was reported in 26% of patients receiving biweekly 
pegloticase, 42% of patients receiving monthly pegloticase, 
and 5% of patients receiving placebo.20 In the OLE, IRs were 
observed in 44% of patients.23 A more detailed analysis of 
IRs was published separately, combining data from both the 
RCTs and the OLE study.28 In the pooled analysis, IRs were 
reported for 94 (45%) of 208 patients treated with pegloticase. 
The most common IRs were chest discomfort (15%), flushing 
(12%), dyspnea (11%), back pain (9%), hyperhidrosis (9%), 
nausea (9%), erythema (9%), urticaria (8%), chest pain (8%), 
pruritus (8%), rash (6%), muscle spasms (6%), headache 
(6%), and abdominal pain (5%). Although most IRs were 
rated mild or moderate in severity, 12 (7%) of 169 patients 
who started pegloticase during the RCTs and 11 (7%) of 149 
patients who received pegloticase in the OLE experienced 
serious adverse reactions. IR was the basis for discontinua-
tion from study drug for 20 patients in the RCTs and for 11 
patients in the OLE study. Fortunately, all IRs resolved with 
supportive measures.28
Most IRs (91%) occurred in patients with pre-infusion 
serum uric acid concentrations >6 mg/dL. For patients sus-
taining pre-infusion serum urate <6 mg/dL, IRs occurred in 
fewer than 1 per 100 infusions. Therefore, IRs are associated 
with reduced urate-lowering efficacy, probably in patients 
who develop antibodies against pegloticase. Data from the 
RCTs revealed that 89% of patients treated presented anti-
bodies against pegloticase.
Seven deaths (4 in the pegloticase group and 3 in the 
placebo group) occurred between randomization for RCTs 
and closure of the study period. Two deaths during the treat-
ment period were attributed to cardiovascular AEs (cardiac 
arrest and arrhythmia), in the biweekly pegloticase group, 
in patients with previous cardiovascular risk factors at 
baseline.22
Discussion
In patients with refractory gout, pegloticase demonstrated 
fast and effective reduction of plasma urate levels, leading to 
reduced frequency of acute flares after 3 months of treatment 
(there are actually more flares during the first months), and 
tophi resolution. It was the first treatment for chronic gout 
demonstrating effectiveness in improving HRQoL and physi-
cal function. However, an important proportion of patients 
develops antibodies against pegloticase, after the first few 
infusions, resulting in reduced urate-lowering efficacy and 
the development of adverse reactions.
Confirming the potential benefits of the treatment with 
pegloticase, a recently published case report described the 
case of a nonagenarian with severe refractory tophaceous 
gout, resulting in functional impairment and loss of auton-
omy. The patient was treated with twice-monthly pegloticase 
infusions for 6 months, resulting in almost complete resolu-
tion of tophi and healing of skin erosions associated with 
them, leading to recovery of the patient’s independence.29
Pegloticase appears to be, indeed, a valuable alternative 
for patients with severe gout who are non-responsive or 
intolerant to other ULTs, having proven its efficacy in several 
patient outcomes. However, some concerns remain about 
cost and safety issues.
Gout flares are frequent in the beginning of treatment, 
especially during the first 3 months of therapy; its occur-
rence seems to be more frequent than with oral ULT agents, 
which, in fact, can be explained by the greater urate-lowering 
capacity of pegloticase. Flare prophylaxis, as recommended 
by international guidelines,7 may be insufficient in these 
patients. Perhaps a more aggressive prophylaxis with colchi-
cine, NSAIDs, and/or corticosteroids, as proposed recently 
by Pascual et al,30 should be adopted.
The risk of cardiovascular events is high among patients 
treated with pegloticase; this was identified as a trend in the 
RCTs22 and confirmed in a nationwide database analysis.28 
Data are not conclusive on whether the higher frequency 
of cardiovascular events is due to treatment itself, to high 
doses of corticosteroids used to prevent gout flares, or to 
the high baseline cardiovascular risk of the patients eligible 
to treatment.
Immunogenicity remains the most relevant issue concern-
ing drug safety and withdrawal. Anti-pegloticase antibodies 
can be identified in a significant percentage of patients and, in 
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and loss of efficacy.31,32 The loss of efficacy of pegloticase, 
translated as pUAc >6 mg/dL, was a good surrogate marker 
for the presence of high titers of anti-pegloticase antibod-
ies and, consequently, helpful to predict the occurrence of 
further infusion reactions. These findings led to the recom-
mendation that the drug should be discontinued in patients 
with 2 sequential determinations of pUAc >6 mg/dL.27 In 
addition, in a trial by Hershfield et al,25 including 7 patients 
who were organ transplant recipients under immunosup-
pressive therapy, anti-plegloticase antibodies were found in 
only 1 of such patients; this finding unveils a possible role 
for concurrent immunosuppressive agents as a strategy to 
reduce antidrug antibody formation and thus avoid infusion 
reactions and loss of efficacy.
Finally, one major consideration to be held is that 
pegloticase trials took place before febuxostat and lesinurad 
were widely available (approved by FDA in 2009 and 2015, 
respectively), thus overestimating the number of patients 
who would benefit from the drug, since febuxostat came up 
as a valid and less expensive option for patients in whom 
allopurinol was contraindicated or uneffective11,12,33,34 and 
lesinurad, in combination with the formerly mentioned 
therapies, demonstrated superior urate-lowering capacity 
to both drugs alone.35,36 Considering costs and safety pro-
file, pegloticase would eventually be the last resource for 
patients who are refractory to other available drugs – alone 
or in combination.
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